Risk of venous thromboembolism among users of oral contraceptives: A review of two recently published studies

Journal of Family Planning and Reproductive Health Care

Volumn 36, Issue 1, 2010, Pages 33-38

  Shapiro, Samuel ^a,b   Dinger, Jürgen ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b BOSTON UNIVERSITY   (United States)

^c Berlin Center for Epidemiology and Health Research   (Germany)

Author keywords

Combined oral contraceptives; Progestogen; Risk assessment; Venous thromboembolism

Indexed keywords

CYPROTERONE; DESOGESTREL; DROSPIRENONE; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

BODY MASS; HUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PRESCRIPTION; PREVALENCE; REVIEW; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DENMARK; DESOGESTREL; ESTROGENS; FEMALE; HUMANS; LEVONORGESTREL; NETHERLANDS; PROGESTERONE; PROGESTINS; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 76149142185     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118910790291037     Document Type: Review

References (42)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
3. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
4. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD.Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-88.
5. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-88.
6. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
7. Farmer RDT, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998; 57: 60-70.
8. Lidegaard Ø, Edstrom B, Kreiner S. Oral contraceptives and VTE: a case control study. Contraception 1998; 57: 291-301.
9. Lewis MA, Heinemann LAJ, McRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5-13.
10. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-134.
11. Heinemann LAJ, Lewis MA, Assmann A, Thiel C. Case-control of studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002; 65: 207-214.
12. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
13. Van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921.
14. IMS MIDAS Quantum. Systemic hormonal contraceptives: Schering goes from strength to strength. http://pharmalicensing.com/public/articles/view/ 1159434559-451b913fa3450 [Accessed 9 November 2009].
15. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives (EURAS-OC) based on 142,475 women-years of observation. Contraception 2007, 75: 344-354.
16. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15: 817-821.
17. Lidegaard Ø. COCs and VTE risks. http://www.bmj.com/cgi/eletters/ 339/aug13-2/b2890#218855 [Accessed 23 November 2009].
18. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143: 697-706.
19. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
20. Nightingale AL, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effect of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000; 5: 265-274.
21. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP Jr. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004; 70: 3-10.
22. Trussell J, Guthrie KA, Schwarz EB. Much ado about little: obesity, combined hormonal contraceptive use and venous thrombosis. Contraception 2008; 77: 143-146.
23. Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-1535.
24. Bezemer ID, van der Meer FJM, Eikenboom JCJ, Rosendaal FR, Doggen CJM. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610-615.
25. Heinemann LAJ, DoMinh T, Assmann A, Schramm W, Schürmann R, Hilpert J, et al. VTE risk assessment - a prognostic model: BATER cohort study of young women. Thromb J 2005; 3: 5.
26. Baron JA, Gridley G, Weiderpass W, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-1080.
27. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep venous thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
28. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
29. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
30. Schwarz T, Siegert G, Oettler W, Halbritter K, Beyer J, Frommhold R, et al. Venous thrombosis after long-haul flights. Arch Intern Med 2003; 163: 2759-2764.
31. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A five-year national case-control study. Contraception 2002; 65: 187-196.
32. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 2. Principles of causality in epidemiological research: confounding, effect modification and strength of association. J Fam Plan Reprod Health Care 2008; 34: 185-190.
33. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 3: Principles of causality in epidemiological research: statistical stability, dose- and duration-response effects, internal and external consistency, analogy and biological plausibility. J Fam Plann Reprod Health Care 2008; 34: 261-264.
34. Lidegaard Ø. Progestagen types in combined OC in Denmark 1985-2004. http://www.lidegaard.dk/Slides/OC%20epidem/PP%2007-11-20%20en.pdf [Accessed 23 November 2009].
35. Szarewski A, Mansour D. COCs and VTE risks. http://www.bmj.com/cgi/ eletters/339/aug13-2/b2890 [Accessed 23 November 2009].
36. Seaman HF, de Vries CS, Farmer RDT. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003; 18: 522-526.
37. Danish National Institute of Public Health. http://susy2.sifolkesundhed. dk/susy.aspx [Accessed 23 November 2009].
38. Lidegaard Ø. Absolute and attributable risk of venous thromboembolism in women on cyproterone acetate. J Obstet Gynaecol Can 2003; 25: 575-577.
39. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002; 324: 869.
40. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
41. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007; 110: 587-593.
42. Dunn N. Oral contraceptives and venous thromboembolism BMJ 2009; 339: b3164.